Abstract PR09: Frequency and etiology of ctDNA-positive metastatic prostate cancer with BRCA2, ATM, or CDK12 mutations
Evan W. Warner(Guardant (United States)), Alexander W. Wyatt(University of British Columbia), Arkhjamil Angeles, Steven Yip(University of Calgary), Arshia Beigi(BC Cancer Agency), Sinja Taavitsainen(Tampere University of Applied Sciences), Elena Schönlau(University of British Columbia), Daniel Khalaf(BC Cancer Agency), Matti Annala(Tampere University), Gillian Vandekerkhove(University of British Columbia), Matti Nykter(University of Liverpool), Gang Wang(Wuhan University), Amanda Wong(University of British Columbia), Kim Chi(BC Cancer Agency), Kevin Beja(University of British Columbia)
Cited by 1
Related Papers
The evolutionary history of lethal metastatic prostate cancer
|Nature|2015|1.4k
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer
|Cancer Discovery|2018|520
Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer
|JAMA Oncology|2016|384
Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair–deficient Prostate Cancer
|European Urology|2017|218
Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer
|European Urology|2019|183